Companies › Liaoning Chengda Biotechnology
3 active drug programs in 3 registered trials: 3 Phase 4; Vaccines, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Liaoning Chengda Inactivated Japanese Encephalitis Vaccine Inactivated Japanese encephalitis virus vaccine | – | Phase 4 | Japanese Encephalitis | Dec 2026 |
| Japanese Encephalitis Vaccine (Vero Cell), Inactivated Inactivated virus vaccine | – | Phase 4 | Japanese Encephalitis Vaccine | Dec 2030 |
| Japanese Encephalitis Vaccine, Live Live attenuated virus vaccine | – | Phase 4 | Japanese Encephalitis Vaccine | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06678373 | Liaoning Chengda Inactivated Japanese Encephalitis Vaccine | Phase 4 | Japanese Encephalitis | Infectious disease | Dec 2026 |
| NCT06825312 | Japanese Encephalitis Vaccine (Vero Cell), Inactivated | Phase 4 | Japanese Encephalitis Vaccine | Vaccines | Dec 2030 |
| NCT06825312 | Japanese Encephalitis Vaccine, Live | Phase 4 | Japanese Encephalitis Vaccine | Vaccines | Dec 2030 |
No annotated target.
–
BioNet-Asia Sinovac Biotech Xiamen Innovax Biotech National Vaccine and Serum Institute, China ARJ Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.